Document Detail


The Evolving Role of β-Adrenergic Receptor Blockers in Managing Hypertension.
MedLine Citation:
PMID:  22595449     Owner:  NLM     Status:  In-Data-Review    
Abstract/OtherAbstract:
β-Adrenergic blocking agents (or β-blockers) have been widely used for the treatment of hypertension for the past 50 years, and continue to be recommended as a mainstay of therapy in many national guidelines. They have also been used in a variety of cardiovascular conditions commonly complicating hypertension, including angina pectoris, myocardial infarction (MI), acute and chronic heart failure, as well as conditions like essential tremor and migraine. Moreover, they have played a primary role in controlling blood pressure in patients with these specific comorbidities and in reducing cardiovascular risk with regard to the composite outcome of death, stroke, and MI among patients younger than 60 years of age. However, in patients 60 years of age or older, β-blockers were not associated with significantly lower rates of MI, heart failure or death, and demonstrated higher rates of stroke compared with other first-line therapies. Consequently, the Canadian Hypertension Education Program recommends the use of β-blockers as first-line therapy in hypertensive patients younger than 60 years of age but not for those age 60 and older, with the exception of patients with concomitant β-blocker-requiring cardiac diseases. Several reports suggest that the lack of consistent outcome data may relate to the use of traditional β-blockers such as atenolol and their ability only to reduce cardiac output, without beneficial effect on peripheral vascular resistance. The present report will describe the clinically relevant mechanisms of action of β-blockers, their pharmacological differences, their metabolic effects, and their usefulness in patients with hypertension.
Authors:
Luc Poirier; Yves Lacourcière
Related Documents :
7530919 - Inhibition of nitric oxide synthesis does not affect ischemic preconditioning in isolat...
1545389 - Effects of diltiazem on glycolysis and oxidative metabolism in the ischemic and ischemi...
8023979 - Coenzyme q10 enhances cardiac functional and metabolic recovery and reduces ca2+ overlo...
15023869 - Fatty acid translocase/cd36 deficiency does not energetically or functionally compromis...
24581559 - Assessment of early onset of driver fatigue using multimodal fatigue measures in a stat...
2401899 - Threshold of carotid artery back pressure for delayed neuronal injury in the hippocampu...
17013659 - Experimental measurement of tibiofemoral contact area in a meniscectomized ovine model ...
6872809 - Achalasia-like esophagus from amyloidosis. successful treatment with pneumatic bag dila...
15080389 - Organizational instability and cardiovascular risk factors in white-collar employees: a...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  The Canadian journal of cardiology     Volume:  28     ISSN:  1916-7075     ISO Abbreviation:  Can J Cardiol     Publication Date:  2012 May 
Date Detail:
Created Date:  2012-05-18     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8510280     Medline TA:  Can J Cardiol     Country:  England    
Other Details:
Languages:  eng     Pagination:  334-40     Citation Subset:  IM    
Copyright Information:
Copyright © 2012 Canadian Cardiovascular Society. Published by Elsevier Inc. All rights reserved.
Affiliation:
Unité d'hypertension, Centre de recherche, Centre Hospitalier Universitaire de Québec, Québec, Québec, Canada.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  The obesity epidemic and its impact on hypertension.
Next Document:  Folate and vitamin B12 deficiency and hyperhomocysteinemia promote oxidative stress in adult type 2 ...